Clinical Trial Update: A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients [Phase 1]

View source ↗

Summary

Phase I study evaluating ABT-888 (veliparib) with temozolomide in patients with various cancers, including metastatic melanoma. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Fallopian Tube Cancer
• Hepatocellular Carcinoma
• Melanoma
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• ABT-888 (veliparib)
• Temozolomide (Temozolomide)

Snippet

Sponsor: AbbVie | Conditions: Non-hematologic Malignancies, Metastatic Melanoma | Phase 1 | Status: COMPLETED